Lattice Semiconductor to Present at the 53rd Annual J.P. Morgan Global Technology, Media and Communications Conference
Ford Tamer, Chief Executive Officer, Lorenzo Flores, Chief Financial Officer, and Rick Muscha, Vice President of Investor Relations, will discuss Lattice Semiconductor's strategy and recent financial results.
A fireside chat with institutional investors will be webcast at 2:30 p.m. Eastern Time on the investor relations section of Lattice Semiconductor's website at www.latticesemi.com.
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive and consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.
For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, X, Facebook, YouTube, WeChat, or Weibo.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 minutes ago
- Business Wire
Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in Saudi Arabia
PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains marketing authorization (MA) and reimbursement status for Sibnayal® (a fixed combination of potassium citrate and potassium bicarbonate) in the Kingdom of Saudi Arabia (KSA). Marketing authorization for Sibnayal® (ADV7103) in distal Renal Tubular Acidosis (dRTA) in KSA has been granted, based on the European registration dossier. Furthermore, Saudi authorities have agreed a reimbursement rate in line with the best European pricing. This achievment results of a close collaboration between Advicenne and its local partner, Taïba Healthcare, a leading distributor of pharmaceutical products in the Gulf region. Advicenne will act as the marketing authorization holder, while Taïba Healthcare will manage local marketing activities. The incidence of dRTA is higher in Gulf countries than in Europe or the United States, and prevalence in KSA could be estimated around 600 to 800 patients. Sibnayal® is already prescribed through early access programs in several Gulf countries outside Saudi Arabia. This milestone paves the way for registrations in GCC countries where the application is filed. Didier Laurens, CEO of Advicenne, declared: 'I am particularly proud of this important achievement and wish to congratulate both Advicenne and Taïba Healthcare teams, whose efforts were instrumental in informing and convincing the Saudi health authorities. The reimbursement obtained, comparable to the highest levels recorded in Europe, further attests to the significant therapeutic value of Sibnayal® in a region with one of the highest prevalence rates of dRTA worldwide.' About Advicenne Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: Disclaimer This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2024 Universal Registration Document filed with the French financial market authority on April 29, 2025 (a copy of which is available on and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.
Yahoo
31 minutes ago
- Yahoo
Kraft Heinz's (KHC) Role in the Food Dividend Market: What Investors Should Know
The Kraft Heinz Company (NASDAQ:KHC) is included among the 10 Best Food Stocks with Dividends. A closeup of an assembly line worker inspecting a newly produced jar of condiments and sauces. As reported by The Wall Street Journal, The Kraft Heinz Company (NASDAQ:KHC) is considering spinning off a significant portion of its operations, potentially valued at around $20 billion. With the company's total market capitalization currently near $34 billion, the move would represent a major restructuring. While specifics haven't been confirmed, reports suggest the split may involve creating one division centered on spreads and sauces, while the other would include processed meats, cheeses, and other essential products. The Kraft Heinz Company (NASDAQ:KHC) reported revenue of $6 billion in the first quarter of 2025, down 6% from the same period last year. The company was once known for steady dividend growth, but after its 2015 merger with Heinz, the company eventually cut its dividend due to underperforming acquisitions. Since early 2019, the dividend has remained at $0.40 per share. However, rising cash flows— growing from $2.46 billion in 2022 to $4.1 billion in 2024— have improved the dividend outlook. In Q1 2025, the company returned $477 million to shareholders through dividends. The Kraft Heinz Company (NASDAQ:KHC) currently pays a quarterly dividend of $0.40 per share and has a dividend yield of 5.58%, as of July 27. While we acknowledge the potential of KHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
33 minutes ago
- Business Insider
‘Momentum Meets Reality,' Says Barclays About Tesla Stock
Tesla (NASDAQ:TSLA) stock took a beating last Thursday, as Elon Musk's powers of persuasion might not be what they used to be. Despite the CEO's best efforts to convince investors that the company's future lies in its AI and Robotaxi initiatives, Wall Street focused instead on the EV leader's underwhelming Q2 results. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Those numbers left little room for optimism. Revenue fell by 11.8% year-over-year to $22.49 billion, missing the Street's $22.74 billion forecast. Operating income slid to $0.9 billion, a 42% drop from the year-ago quarter. The end result was adjusted EPS of $0.40, falling short of expectations by $0.03. But beyond the headline misses, what truly spooked investors were the signals about what lies ahead. Tesla now faces a growing list of challenges that could further weigh on performance. With the U.S. EV tax credit set to expire at the end of Q3, even Musk acknowledged that the company might endure a few 'rough quarters.' That outlook is further clouded by the impact of tariffs and legislative changes –particularly Trump's One Big Beautiful Bill, which eliminated penalties tied to NHTSA CAFE emissions standards. This change is expected to drag on high-margin regulatory credit sales. For Barclays analyst Dan Levy, what's become 'abundantly clear' for Tesla over the past couple of years – particularly in the last year – is the 'widening gulf between narrative and fundamentals, with the stock increasingly disconnected from fundamentals.' This quarter 'further reinforced that gulf.' Still, Musk isn't shying away from promoting the bigger vision. He reiterated that Tesla's future reaches far beyond cars, spotlighting AI and robotics as the company's next frontier. From Robotaxis and Optimus to a newly envisioned 'master plan' for a post-autonomy world, the CEO painted a picture of a company leading the charge in real-world AI. Musk even floated the idea of closer collaboration with xAI to bolster Tesla's technological edge. 'Alongside comments of expansion in Robotaxi,' says Levy, 'we believe the narrative remains intact.' However, a compelling narrative can only do so much when fundamentals are shaky. As Levy pointed out, Tesla's core business remains choppy, and could worsen in the quarters ahead. Even the anticipated low-cost model, now likely arriving in Q4, may underwhelm if it's merely a simplified Model Y with limited appeal. In the end, the earnings call seemed tailored to reassure long-term believers in Tesla's AI potential rather than to win over skeptics focused on near-term performance. The lack of new detail on Robotaxi progress didn't help, though bulls may pin their hopes on the upcoming AGM in November, which could reinforce the AI story. 'It is the long-term narrative which has kept the stock elevated,' Levy noted. 'Yet for the very near term, the air pocket in fundamentals may be a reminder that fundamentals don't matter… until they matter.' Judging by the market's reaction, that moment may be arriving. For now, Levy assigns Tesla shares an Equal Weight (i.e., Neutral) rating, with a $275 price target, implying potential downside of 13% from current levels. (To watch Levy's track record, click here) Looking beyond Levy, sentiment across Wall Street remains divided. TSLA stock holds a consensus rating of Hold, based on 14 Buys, 14 Holds, and 7 Sells. The average price target of $314.14 suggests shares will stay rangebound for the time being. (See TSLA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
